Literature DB >> 14689092

[Hypogonadism in the elderly man. Reliable diagnosis and therapy].

M Zitzmann1, E Nieschlag.   

Abstract

The definition of late-onset-hypogonadism as a hybrid form of primary and secondary hypogonadism corresponds to pathophysiological facts of the age-related decline in gonadal as well as hypothalamic-pituitary functions, eventually manifesting in clinically relevant hypogonadism. To what extent advancing age modulates incidence and nature of hypogonadal symptoms has not been completely investigated. The benefits of testosterone substitution therapy in older men await demonstration in long-term studies and to date, it should be restricted to specialized centers. Currently, serum testosterone levels <12 nmol/l, accompanied by symptoms of androgen deficiency, are regarded as an indication for substitution, provided a prostate carcinoma has been excluded. While late-onset hypogonadism decreases libido, it does not play a direct role in the increasing incidence of erectile dysfunction with advancing age; this symptom is rather associated with vessel-endothelial impairment and may serve as a sentinel symptom for cardiovascular disease. Treatment with phosphodiesterase-5-inhibitors can be regarded as standard; in case of concomitant late-onset hypogonadism, testosterone will have a positive synergistic effect on erectile function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14689092     DOI: 10.1007/s00108-003-1044-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  34 in total

1.  The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum concentrations of leptin and insulin in men.

Authors:  M Zitzmann; J Gromoll; A von Eckardstein; E Nieschlag
Journal:  Diabetologia       Date:  2002-12-20       Impact factor: 10.122

2.  Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging.

Authors:  S M Harman; E J Metter; J D Tobin; J Pearson; M R Blackman
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

3.  The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. The coronary Drug Project Research Group.

Authors: 
Journal:  JAMA       Date:  1973-11-05       Impact factor: 56.272

4.  Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males.

Authors:  A Vermeulen; J M Kaufman; V A Giagulli
Journal:  J Clin Endocrinol Metab       Date:  1996-05       Impact factor: 5.958

5.  Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.

Authors:  Sigrid von Eckardstein; Eberhard Nieschlag
Journal:  J Androl       Date:  2002 May-Jun

Review 6.  Dehydroepiandrosterone (DHEA) supplementation for cognition and well-being.

Authors:  F A Huppert; J K Van Niekerk; J Herbert
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 7.  DHEA treatment: myth or reality?

Authors:  Bruno Allolio; Wiebke Arlt
Journal:  Trends Endocrinol Metab       Date:  2002-09       Impact factor: 12.015

8.  Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.

Authors:  Sylvia Wassertheil-Smoller; Susan L Hendrix; Marian Limacher; Gerardo Heiss; Charles Kooperberg; Alison Baird; Theodore Kotchen; J David Curb; Henry Black; Jacques E Rossouw; Aaron Aragaki; Monika Safford; Evan Stein; Somchai Laowattana; W Jerry Mysiw
Journal:  JAMA       Date:  2003-05-28       Impact factor: 56.272

9.  Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction.

Authors:  Antonio Aversa; Andrea M Isidori; Giovanni Spera; Andrea Lenzi; Andrea Fabbri
Journal:  Clin Endocrinol (Oxf)       Date:  2003-05       Impact factor: 3.478

10.  Contraceptive steroids influence the hemostatic activation state in healthy men.

Authors:  Michael Zitzmann; Ralf Junker; Axel Kamischke; Eberhard Nieschlag
Journal:  J Androl       Date:  2002 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.